Breast cancer in 2020: What can we expect?

Cancer Detection and Prevention

Volumn 30, Issue 2, 2006, Pages 109-110

  Horton, John ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; EDITORIAL; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; FORECASTING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MEDICAL ONCOLOGY;

EID: 33646801966     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2006.03.003     Document Type: Editorial

References (10)

1. Horton J. Breast cancer. In: Horton J., and Hill G. (Eds). Clinical Oncology (1977), WB Saunders, Philadelphia, PA 366-389
2. Newman B., and Liu E.T. Perspective on BRCA1. Breast Dis 10 1-2 (1998) 3-10
3. Dumitrescu R.G., and Cotarla I. Understanding breast cancer risk-where do we stand in 2005?. J Cell Mol Med 9 1 (2005) 208-221
4. Hartman A.R. The problems with risk selection; scientific and psychosocial aspects. Recent Results Cancer Res 166 (2005) 125-144
5. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23 8 (2005) 1636-1643
6. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (2005) 1784-1792
7. van't Veer L.J., Paik S., and Hayes D.F. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 23 8 (2005) 1631-1635
8. Burak W.E., Hollenbeck S.T., Zervos E.E., Hock K.L., Kemp L.C., and Young D.C. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 183 1 (2002) 23-27
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
10. The HERA Study Team. Trastuzumab following adjuvant chemotherapy significantly improves disease-free survival in early breast cancer with HER2 overexpression: the HERA trial. Breast Cancer Res Treat 94 Suppl 1 (2005) 8 [Abstract]